

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
28 February 2002 (28.02.2002)

PCT

(10) International Publication Number  
WO 02/15931 AI

(51) International Patent Classification?: A61K 39/40,  
A61P 31/04, A61K 7/16 // C07K 16/12, 16/00

(21) International Application Number: PCT/US00/23277

(22) International Filing Date: 24 August 2000 (24.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicants (for all designated States except US): WASH-  
INGTON DENTAL SERVICE [US/US]: 9706 Fourth  
Avenue, Seattle, WA 98115 (US). REGENTS OF THE  
UNIVERSITY OF CALIFORNIA [US/US]: 1111  
Franklin Street, Oakland, CA 94607-5200 (US).

(72) Inventors: and

(75) Inventors/Applicants (for US only): SHI, Wenyuan  
[CN/US]: 7011 Kenwood Avenue, Los Angeles, CA  
90045 (US). ANDERSON, Maxwell, H. [US]: 519 North  
62nd Street, Seattle, WA 98103 (US).

(74) Agent: MEYER, David, J.: Manett, Phelps & Phillips.  
LLP, 11355 West Olympic Boulevard, Los Angeles, CA  
90064 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): European patent (AT, BE,  
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE).

Published:  
— with international search report

(48) Date of publication of this corrected version:  
23 May 2002

(15) Information about Correction:  
see PCT Gazette No. 21/2002 of 23 May 2002, Section II

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

WO 02/15931 AI

(54) Title: IMMUNOLOGIC METHOD FOR THE PREVENTION OF DENTAL CARIES

(57) Abstract: Dental caries in man may be prevented or treated by oral ingestion of human or humanized mouse monoclonal IgG and IgM antibodies that bind to surface antigens of cariogenic organisms, such as *S. mutans*. The genetically immune system when they bind to cariogenic organisms, resulting in their destruction. In a preferred embodiment, monoclonal antibodies to cariogenic organisms are produced by edible plants, including fruits and vegetables, transformed by DNA sequences that code on expression for the desired antibodies. The antibodies are applied by eating the plants.

- 1 -

## IMMUNOLOGIC METHOD FOR THE PREVENTION OF DENTAL CARIES

Background of the Invention

5 This application relates to an immunologic methodology for the treatment and prevention of dental caries. This invention has special application to patients who are without the ability or motivation to apply established principles of self care, such as very young children, the infirm and poorly educated populations.

10 Dental caries (tooth decay) and periodontal disease are probably the most common chronic diseases in the world. The occurrence of cavities in teeth is the result of bacterial infection. Hence the occurrence of dental caries is properly viewed as an infectious microbiological disease that results in localized destruction of the calcified tissues of the teeth.

15 *Streptococcus mutans* is believed to be the principal cause of tooth decay in man. When *S. mutans* occurs in large numbers in dental plaque, and metabolizes complex sugars, the resulting organic acids cause demineralization of the tooth surface. The result is carious lesions, commonly known as cavities. Other organisms, such as *Lactobaccilli* and *Actinomyces* are also believed to be involved in the progression and formation of carious lesions. Those organizations that cause tooth decay are referred to herein as "cariogenic organisms."

20 Removal of the damaged portion of a tooth and restoration by filling can, at least temporarily, halt the damage caused by oral infection with cariogenic organisms. However, the "drill and fill" approach does not eliminate the causative bacterial agent. Proper oral hygiene can control the accumulation  
25 of dental plaque, where cariogenic organisms grow and attack the tooth surfaces.

- 2 -

5 However, dental self-care has its limits, particularly in populations that are unable to care for themselves, or where there is a lack of knowledge of proper methods of self care. Administration of fluoride ion has been shown to decrease, but not eliminate the incidence of dental caries.

10 In view of the overwhelming evidence of the involvement of cariogenic organisms in the pathogenesis of dental caries, it is not surprising that there have been a number of different attempts to ameliorate the condition using traditional methods of anti-microbial therapy. The disadvantage of antimicrobial agents is that they are not selective for cariogenic organisms. Administration of non-specific bacteriocidal agents disturbs the balance of organisms that normally inhabit the oral cavity, with consequences that cannot be predicted, but may include creation of an environment that provides opportunities for pathogenic organisms. In addition, long term use of antimicrobial agents is known to select for organisms that are resistant to them. Hence long term and population-wide use of antimicrobial agents to prevent tooth decay is not practical.

15 Vaccination of humans to elicit an active immune response to *S. mutans*, or other cariogenic organisms, is also not a practical solution at this time. One drawback of this approach is that vaccination elicits production of predominantly IgG and IgM antibodies, but they are not secreted into saliva. The majority of antibodies present in saliva are of the IgA isotype, which can bind to, but cannot activate lymphocytes or complement components to kill bacteria. Accordingly, vaccination is not believed likely to be capable of producing antibodies that can trigger the immune system to kill cariogenic organisms in the mouth. There is no known method for selectively increasing the titer of vaccination induced antibodies of the IgG or IgM isotypes in the oral cavity.

20  
25 There have been a number of reported attempts to passively immunize patients to *S. mutans* using monoclonal IgA antibodies raised in mice to prevent tooth decay in animals and in man. Because IgA is a multivalent antibody, a single molecule of IgA can bind to several different antigenic sites, resulting in clumping of bacteria. However, binding of IgA to bacterial surface antigens does not  
30

- 3 -

kill the bacteria. Rather, clumping is believed to hinder the ability of bacteria to bind to tooth surfaces. Another drawback of this approach is that repeated administration of mouse (i.e., heterologous) antibodies to humans has the potential to evoke an immune response to the antibodies.

5 Unlike IgA antibodies, antibodies of the IgG and IgM classes have bacteriocidal effects. Binding of IgM or IgG antibodies to antigens present on the surface of cariogenic organisms may result in the destruction of the bacterial cells by two separate mechanisms: complement mediated cell lysis and antibody-dependent cell-mediated cytotoxicity. In either case, antibodies that selectively  
10 bind to certain microbial organisms target just those cells for destruction by the immune system. Both complement mediated cell lysis and antibody-dependent cell mediated cytotoxicity are part of the humoral immune response that is mediated by antibodies of the IgG and IgM classes.

In order to elicit the desired cytotoxic effect of antibody binding, monoclonal antibodies to cariogenic organisms must be recognized by the human  
15 immune system. There are a number of different technologies by which antibodies that will trigger a response from a heterologous mammalian immune system can be produced. One example is a nucleic acid construct that codes on expression for a human antibody modified to incorporate sequences encoding the antigen specific binding domain from heterologous organisms.

20 Production and administration of such genetically engineered monoclonal antibodies to treat dental caries in man poses issues susceptible to a particularly innovative solution. Prior art methods for production of monoclonal antibodies involve growing hybridomas in culture media, followed by extraction and purification of the desired antibody. These steps are significantly simplified in a preferred embodiment of the invention by expressing the antibodies in edible plants or animals (eukaryotes). The antibodies are administered upon oral  
25 ingestion of plant or animal products, such as fruits, vegetables or milk wherein the antibodies are not denatured. This mode of administration has the potential for obviating compliance issues in ameliorating tooth decay.

- 4 -

Summary of the Preferred Embodiments

5                   Dental caries may be prevented or treated by oral ingestion of  
                  human or humanized mouse monoclonal IgG and IgM antibodies that to bind  
                  surface antigens of cariogenic organisms, such as *S. mutans*. The genetically  
                  engineered monoclonal antibodies engage the effector apparatus of the human  
10                  immune system when they bind to cariogenic organisms, resulting in their  
                  destruction. In a preferred embodiment, monoclonal antibodies to cariogenic  
                  organisms are produced by edible plants, including fruits and vegetables,  
                  transformed by DNA sequences that code on expression for the desired  
                  antibodies. The antibodies are applied by eating the plants.

- 5 -

Detailed Description of the Preferred Embodiments1. Preparation of Monoclonal Antibodies

5 The monoclonal antibody technique permits preparation of a source of antibodies with extraordinary specificity. Monoclonal antibodies that bind to specific molecular structures can be produced using what are today considered standard techniques.

10 The monoclonal antibodies that may be used in this invention are those that are directed to surface antigens of cariogenic organisms. Surface antigens are substances that are displayed on the surface of cells. Such antigens are accessible to antibodies present in body fluids. In the context of the present invention, surface antigens of cariogenic organisms are present on the surface of organisms that cause dental caries. While the role of bacterial activity in the genesis of carious lesions is well defined, establishing a cause and effect relationship between a particular organism and the occurrence of dental caries has not been completely successful. To date, only *S. mutans* has been definitively associated with dental caries. However, species of the *Lactobacilli* and *Actinomyces* are also believed to be involved, particularly with the active progression of carious lesions. Any organism that can produce a carious lesion is a potential target for the monoclonal antibodies prepared and used in accordance with this invention.

20 A further requirement of the monoclonal antibodies that may be used in the practice of the present invention is that they are selective for cariogenic organisms. Monoclonal antibodies directed to antigens present on cariogenic as well as non-cariogenic organisms may produce non-specific alterations in the makeup of the flora within the oral cavity. The consequences of such changes are not understood.

25 Accordingly, the preferred monoclonal antibodies are directed to surface antigens of cariogenic organisms. That is to say, the preferred monoclonal antibodies bind specifically to organisms that cause dental caries.

- 6 -

It should be clearly understood that the scope of the present invention is not limited to the prevention of tooth decay in man. Monoclonal antibodies in accordance with the present invention can be genetically engineered to engage the effector response of the immune system of other mammals, such as those that are domesticated as pets.

Monoclonal antibodies are prepared by immunizing mice or other mammalian hosts with cell wall material isolated from cariogenic organisms. In a preferred embodiment, the cariogenic organisms are type c *S. mutans* (ATCC25175). The immunogenicity of molecules present in cell walls may be enhanced by a variety of techniques known in the art. In a preferred embodiment, immunogenicity of such molecules is enhanced by denaturation of the isolated cell material with formalin. Other techniques for modifying cell wall proteins to enhance immunogenicity are within the scope of this invention. Typically, hosts receive one or more subsequent injections of isolated bacterial cell fragments to increase the titer of antibodies prior to sacrifice and cloning.

Spleen cells from hosts are harvested and cloned by limiting dilution using techniques that have become standard since the pioneering work of Kohler and Milstein. In a preferred embodiment, surviving hybridomas are screened for antibody directed to cariogenic organisms by ELISA assay against microtiter plates coated with formalinized bacterial cell material. Positive supernatants may be subjected to further screening to identify clones that secrete antibodies with the greatest affinity for the cariogenic organisms. In a preferred embodiment, clones with titers at least three times higher than background are screened again using an immunoprecipitation against denatured cell wall material from *S. mutans*. In a preferred embodiment, three clones were identified which bound detectably only to *S. mutans* strains ATCC25175, LM7, OMZ175 and ATCC31377. These clones were deposited with the American Type Culture Collection, receiving Deposit Numbers HB-1 2560, 12599 and 12558.

- 7 -

2. Preparation of Monoclonal Antibodies Capable Of Eliciting An Effector Response From Human Immune System

5 Previous efforts to develop an immunological method for the prevention of dental caries employed heterologous antibodies. For example, Lehner, United States patent 5,352,446, referred to use of monoclonal antibodies to *S. mutans* surface antigens raised in mice in inhibiting the proliferation of those bacteria in monkeys. More recently, Ma et al. *Nature Medicine*, 45(5) 601-6 (1998), reported similar results in humans, using a genetically engineered secretory monoclonal antibody to *S. mutans* expressed in tobacco plants. 10 Drawbacks to this approach include 1) administration of heterologous antibodies may aggregate the offending organisms, but will not kill them because such antibodies will not elicit an immune response; and 2) repeated administration of the antibody may elicit an immune response from the patient to the antibody. A preferable approach is to use recombinant techniques to prepare chimeric antibody molecules directed specifically to surface antigens of cariogenic organisms, that will also elicit an effector response from the human immune system (when used in man) upon binding to the target organism. This can be accomplished by inserting variable regions or complementarity determining regions ("CDR's") from mouse monoclonal antibodies that are specific to cariogenic organisms into antibodies of the IgG and/or IgM classes from the mammal to be treated. When the mammal to be treated is man, the antibodies are said to be "humanized."

15 There are various ways to obtain nucleic acid sequences that code on expression for human or humanized monoclonal antibodies to surface antigens of cariogenic organisms: 1) Isolating mouse hybridomas which produce monoclonal antibodies against cariogenic organisms and cloning mouse genes that code on expression for those antibodies; 2) Using purified cariogenic organisms to screen a phage display random library made from human B lymphocytes to obtain genes that encode antibodies specific for cariogenic organisms; 3) Isolating human hybridomas that produce monoclonal antibodies against cariogenic organisms, using B lymphocytes recovered from heavily 25 30

- 8 -

5 infected patients and cloning the human genes encoding for these antibodies; or  
4) immunizing human B lymphocytes and spleen cells *in vitro* using purified  
cariogenic organisms, followed by fusion to form hybridomas to create immortal  
cell lines. The techniques required are known to those skilled in the art.

10 In the presently preferred embodiment of the invention, mouse  
monoclonal antibodies are "humanized." Using the PCR or Southern blot  
technique, DNA fragments encoding the variable domains of mouse hybridomas  
secreting antibody specific to cell surface antigens of cariogenic organisms are  
isolated. Using gene cloning techniques, the variable regions of human IgG and  
IgM immunoglobulin are replaced with the corresponding mouse variable regions  
or CDR's. The result of this genetic engineering is a chimeric antibody molecule  
with variable domains that selectively bind to surface antigens of cariogenic  
organisms, but which interacts with the human immune system through its  
constant regions to trigger a humoral immune response.

15  
3. Administration of Monoclonal Antibodies

20 In order to prepare a sufficient quantity of monoclonal antibodies  
for clinical use, the desired cell line transfected with IgG or IgM encoding  
sequences must be propagated. Existing technology permits large scale  
propagation of monoclonal antibodies in tissue culture. The transfected cell lines  
will secrete monoclonal antibodies into the tissue culture medium. The secreted  
monoclonal antibodies are recovered and purified by gel filtration and related  
25 techniques of protein chemistry.

30 In experimental studies, monoclonal antibodies to *S. mutans* have  
been applied directly to the surface of teeth. Application by ingestion of  
mouthwash, or by chewing gum has also been proposed. A presently preferred  
alternative is to express the monoclonal antibodies of the present invention in  
edible plants, such as banana or broccoli. Eating plants transformed in  
accordance with this invention will result in application of the antibodies to  
cariogenic organisms present on tooth surfaces, and elsewhere in the mouth. It is  
also contemplated that other organisms,

- 9 -

both plant and animal may be transformed to express the monoclonal antibodies described herein, so that such antibodies may be ingested, for example, by drinking milk.

- 10 -

Examples1. Producing mouse monoclonal antibodies against *S. mutans*

Type c *S. mutans* strain ATCC25175 are grown to log phase in BHI medium and washed twice with phosphate buffered saline, pH 7.2 (PBS), by centrifugation at 3000xg for 5 min. The pellet is resuspended in 1% formalin/0.9% NaCl, mixed at room temperature for 30 min and washed twice with 0.9% NaCl. BALB/c mice (8-10 weeks) are immunized intraperitoneally with 100 FI of the antigen containing approximately  $10^8$  whole cells of formalinized intact *S. mutans* bacteria emulsified with Freund's incomplete adjuvant (FIA). After 3-5 weeks, mice will receive a second dose of antigen ( $10^8$  whole cells of bacteria in FIA). Three days prior to fusion, the mice are boosted intravenously with  $10^8$  whole cells in saline.

The standard tissue culture media is RPMI 1640 (Gibco) medium supplemented with 2 mM L-glutamine, 1mM sodium pyruvate, and 10 mM HEPES and containing 100  $\mu$ g/ml penicillin and 100 /  $\mu$ g/ml streptomycin with 10% fetal calf serum. Hybrids are selected in media containing HAT (100 $\mu$ g Hypoxanthine, 0.4.  $\mu$ M Aminopterin; 16  $\mu$ M Thymidine). HT (100  $\mu$ g Hypoxanthine; 16  $\mu$ M Thymidine) is maintained in the culture medium for 2 weeks after aminopterin is withdrawn. OPI (1 mM oxaloacetate, 0.45 mM pyruvate and 0.2 U/ml bovine insulin) is added as an additional growth factor to the tissue culture during cloning of hybridomas. Hybridomas are raised according to the procedure reported by Liddell and Cryer (A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, Chichester, England, 1991). The NSI/A94.1 mouse myeloma cell line is used as the fusion partner and grown in spinner cultures in 5% CO<sub>2</sub> at 37°C and maintained in log phase of growth prior to fusion.

The following approach is used for screening for species-specific monoclonal antibodies against *S. mutans*. The initial screening is performed using an ELISA assay, which selects for the culture supernatants containing antibodies that bind to *S. mutans*. Formalinized bacteria are diluted in PBS to

- 11 -

OD<sub>600</sub> = 0.5, and added to duplicate wells (100 $\mu$ l) in 96 well PVC ELISA plates preincubated for 4 h with 100  $\mu$ l of 0.02 mg/ml Poly-L-lysine. These antigen-coated plates are incubated overnight at 4°C in a moist box then washed 3 times with PBS and blocked with 0.5% fetal calf serum in PBS and stored at 4°C. 100  $\mu$ l of mature hybridoma supernatants are added to the appropriate wells of the antigen plates, incubated for 1 h at room temperature, washed 3 times with PBS-0.05% tween 20, and bound antibody is detected by the addition of polyvalent goat-anti-mouse IgG antibody conjugated with alkaline phosphatase diluted 1:1000 with PBS-1% fetal calf serum. After the addition of the substrate, 1 mg/ml p-nitrophenyl phosphate in carbonate buffer (15 mM Na<sub>2</sub>CO<sub>3</sub>, 35 mM NaH<sub>2</sub>CO<sub>3</sub>, 10 mM MgCl<sub>2</sub> pH 9.6), the color developments after 15 min is measured in an EIA reader at 405 nm. The positive supernatants (3 fold higher than control) are then subjected to the immunoprecipitation assay (mixing 100 $\mu$ l bacteria with 100 $\mu$ l supernatant) to screen for those with strong positive reactivity with *S. mutans*. The deposited clones were prepared according to this method.

2. Generating mouse/human chimeric genes which encode humanized monoclonal antibodies against *S. mutans*.

Described here is one of the ways to humanize mouse monoclonal antibodies. Genomic DNA of mouse hybridoma cell lines is isolated using the QIAamp system (Qiagen, Valencia, CA). After digestion with various restriction enzymes, DNA fragments are fractionated through 0.8% agarose gel by electrophoresis and transferred to a nitrocellulose membrane. Southern blotting is performed to identify the immunoglobulin gene. The heavy chain gene is probed with a DNA fragment from a mouse IgG heavy-chain gene that includes the J3 and J4 segments and the enhancer region. The light chain gene is probed with a DNA fragment from a mouse IgG light-chain gene containing J1-5 segments.

DNA restriction fragments of the selected size identified through Southern blot analysis are purified from agarose gel using Qiagen DNA Clean-up and Gel extraction system. The DNA is ligated into the Lambda-Zap 11 vector

- 12 -

(Stratagene) to construct heavy- and light-chain libraries of these mouse hybridomas in lambda phage. The libraries are screened with heavy- and light-chain J-region probes as mentioned above. DNA of the positive clones is isolated, subcloned and sequenced. To achieve the best accuracy, both sense and antisense strands are sequenced. BLAST search is employed to translate the nucleotide sequence into the amino acid sequence and compare it with the existing antibody genes. The variable region of the heavy-chain is identified, subcloned and inserted into an expression vector which contains a DNA fragment encoding the human IgG heavy chain constant region and the *Ecogpt* gene providing resistance to mycophenolic acid. The variable region of the light-chain is also identified, subcloned and inserted into another expression vector which includes a DNA fragment encoding the human IgG light chain constant region and the neo gene giving resistance to G418.

3. Expressing Monoclonal Antibodies to *S. mutans* In Transformed Organisms

a) Producing human or humanized monoclonal antibodies in animal cells

The heavy and light chain of a human IgG gene are separately introduced or cotransfected into an animal cell line (such as SP2/0) using a lipofection reagent (BRL, Grand Island, NY). The transfected cells are incubated at 37°C in a 5% CO<sub>2</sub> atmosphere in 1x zinc option medium for 24 h and then in medium containing 10% fetal bovine serum. After 48 h incubation, the cells are transferred to a microtiter plate and grown in selection medium containing G418 and mycophenolic acid. The supernatants of drug-resistant cells are collected and screened for immuno-reactivity against *S. mutans* using the ELISA or precipitation assays mentioned above.

- 13 -

b) Producing human or humanized monoclonal antibodies in edible plants

Transgenic plants have been recognized as very useful systems to produce large quantities of foreign proteins at very low cost. Expressing human or humanized monoclonal antibodies against *S. mutans* in edible plants (vegetables or fruits) allows direct application of plant or plant extracts to the mouth to treat existing dental caries and to prevent future bacterial infection. The choice of transgenic, edible plants includes, but is not limited to, potato, tomato, broccoli, and banana.

Presented here are the procedures to produce transgenic *Arabidopsis*, an edible plant closely related to *Brassica* species including common vegetables such as cabbage, cauliflower and broccoli. It is chosen because many genetic and biochemical tools have been well developed for this plant. There are several strategies to express IgG in this plant. One strategy is to first introduce the human IgG genes encoding the heavy chain and light chain to two separate transgenic lines. The two genes are brought together by genetic crossing and selection. Other methods involve sequential transformation, in which transgenic lines transformed with one IgG gene are re-transformed with the second gene. Alternatively, genes encoding the heavy chain and light chain are cloned into two different cloning sites in the same T-DNA transformation vector under the control of two promoters, and the expression of both genes can be achieved by the transformation of a single construct to plant. Technically, the separate transformation method is the simplest one and it usually results in higher antibody yield. Therefore, we present this strategy here. It is possible to transform other plants using similar techniques.

The DNA fragments encoding the heavy and light chains of a human IgG gene are separately cloned into a Ti plasmid of *Agrobacterium tumefaciens*. The plasmid contains a promoter to express human heavy and light chains of IgG in *Arabidopsis thaliana*, an antibiotic marker for selection in *Agrobacterium tumefaciens* and an herbicide resistance gene for transformation selection in *Arabidopsis*. An *Agrobacterium tumefaciens* strain is transformed

- 14 -

with these plasmids, grown to late log phase under antibiotic selection, and resuspended in infiltration medium described by Bethold et al. (C.R. Acad. Sci. Paris Life Sci. 316:1194-1199, 1993).

5 Transformation of *Arabidopsis* by Ti-plasmid containing  
*Agrobacterium tumefaciens* is performed through vacuum infiltration. Entire  
plants of *Arabidopsis* are dipped into the bacterial suspension. The procedure is  
performed in a vacuum chamber. Four cycles of 5 min vacuum (about 40 cm  
10 mercury) are applied. After each application, the vacuum is released and  
reapplied immediately. After infiltration, plants are kept horizontally for 24 h in a  
growth chamber. Thereafter, the plants are grown to maturity and their seeds are  
harvested. The harvested seeds are germinated under unselective growth  
condition until the first pair of true leaves emerged. At this stage, plants are  
15 sprayed with the herbicide Basta at concentration of 150 mg/l in water. The  
*aribidopsis* plants containing transformed Ti plasmids are resistant to the  
herbicide while the untransformed plants are bleached and killed. Such a  
selection continues to the second generation of the plants. For the resistant  
plants, total genomic DNA is isolated and probed with the DNA fragments  
20 encoding heavy and light chains of the IgG gene. The plant extracts from the  
positive transformants are prepared and screened for the expression of human  
IgG protein with Western blot using antibodies against heavy and light chains of  
constant regions of human IgG.

The plants expressing human IgG heavy chain are sexually  
crossed with plants expressing human IgG light chain to produce progeny  
expressing both chains. Western blotting is used to screen the both heavy and  
light chains. Extracts from positive transformants are collected and screened for  
25 immuno-reactivity against *S. mutans* using the ELISA or precipitation assays  
mentioned above.

- 15 -

4. Using human or humanized monoclonal antibodies against  
*S. mutans* to treat or prevent human dental caries

5 With the successful completion of the above studies, humanized monoclonal antibodies against *S. mutans* are obtained. The plant tissue is tested for efficacy.

10 Plant tissue extracts containing monoclonal antibodies to *S. mutans* are mixed with various concentrations of *S. mutans* in the presence and absence of purified human complement components or purified human polymorphonuclear neutrophilic leukocytes. After a two hour incubation, the mixtures are plated onto BHI plates to examine the bactericidal activity.

15 Using the artificial plaque formation system developed by Wolinsky et al. (J. Dent. Res. 75:816-822, 1996), plant tissue extracts containing monoclonal antibodies are used to examine the ability of the expressed monoclonal antibodies ability to kill *S. mutans* in saliva or in existing dental plaques on artificial dental enamel. Analogous techniques are used to examine the ability to prevent the formation of dental plaques.

20 Human clinical trials are performed using these monoclonal antibodies produced through animal cells or plants. Human volunteers are treated with or without these human monoclonal antibodies against *S. mutans*. Then the level of *S. mutans* in saliva and in dental plaques is examined. The correlation between present and future dental caries in relationship with treatment of monoclonal antibodies is also examined.

25 It should be understood that the foregoing examples are for illustrative purposes only, and are not intended to limit the scope of applicants' invention which is set forth in the claims appearing below.

- 16 -

## CLAIMS

What is claimed is:

5 1. A method for treatment and prevention of dental caries in a mammal comprising oral administration of a monoclonal antibody that specifically binds to a cariogenic organism, and which elicits a humoral immune response from the mammal, wherein the monoclonal antibody is derived from a species other than the mammal to be treated.

10 2. The method for treatment and prevention of dental caries of claim 1 wherein the monoclonal antibody is produced by the steps of:

- 15 a) inoculating a mammalian host with at least one cariogenic organism;
- b) identifying hybridomas from the mammalian host that secrete antibodies specific to surface antigens of at least one cariogenic organism; and
- 20 c) preparing a chimeric monoclonal antibody comprising complementarity-determining regions from the monoclonal antibody of step b) above and a constant domain from the mammal to be treated.

25 3. The method for treatment and prevention of dental caries of claim 2 wherein the step of preparing further comprises synthesis of a nucleic acid construct comprising:

- 30 a) a nucleic acid sequence that codes on expression for a complementarity determining region of the monoclonal antibody secreted by the hybridomas derived from the mammalian host of claim 2 above; and
- b) a nucleic acid sequence that codes on expression for a constant region of an antibody selected from the group of class IgG and class IgM of the mammal to be treated.

- 17 -

4. The method for treatment and prevention of dental caries of claim 3 wherein the chimeric monoclonal antibody is expressed by a eukaryotic host that has been transformed with the nucleic acid construct of claim 3 above.

5. The method for treatment and prevention of dental caries in a mammal of claim 4, wherein the monoclonal antibody is administered by oral ingestion of tissue from a eukaryotic host transformed with the nucleic acid construct of claim 4 above.

6. The method for treatment and prevention of dental caries of claim 1 wherein the mammal to be treated is man, and the other species is mouse.

7. A method for treatment and prevention of dental caries in a mammal comprising administration of a monoclonal antibody that specifically binds to a cariogenic organism, and which elicits a humoral immune response from the mammal.

8. The method for treatment and prevention of dental caries of claim 7 wherein the monoclonal antibody is produced by the steps of:

- a) inoculating a mammalian host with at least one cariogenic organism;
- b) identifying hybridomas from the mammalian host that secrete antibodies specific to surface antigens of at least one cariogenic organism; and
- c) preparing a chimeric monoclonal antibody comprising complementarity-determining regions from the monoclonal antibody of step b) above and a constant domain from a mammal to be treated.

- 18 -

9. The method for treatment and prevention of dental caries of claim 8 wherein the step of preparing further comprises preparation of at least one nucleic acid construct that includes:

- a) a nucleic acid sequence that codes on expression for a complementarity determining region of the monoclonal antibody secreted by the hybridomas derived from the mammalian host of claim 2 above; and
- b) a nucleic acid sequence that codes on expression for a constant region of an antibody selected from the group of class IgG and class IgM of the mammal to be treated.

10. The method for treatment and prevention of dental caries of claim 9 wherein the chimeric monoclonal antibody is expressed by a eukaryotic host that has been transformed with the nucleic acid construct of claim 9 above.

11. The method for treatment and prevention of dental caries in a mammal of claim 9, wherein the monoclonal antibody is administered by oral ingestion of tissue from a eukaryotic host that has been transformed with the nucleic acid construct of claim 9 above.

12. The method for treatment and prevention of dental caries of claim 8, wherein the mammalian host is a mouse, and the mammal to be treated is man.

13. The method for treatment and prevention of dental caries of claim 5 wherein the eukaryote is a plant.

14. The method for treatment and prevention of dental caries of claim 5 wherein the eukaryote is a plant of the species *Brassica*.

- 19 -

15. The method for treatment and prevention of dental caries of claim 11 wherein the eukaryote is a plant.

5 16. The method for treatment and prevention of dental caries of claim 11 where the eukaryote is a plant of the species *Brassica*.

17. The method for treatment and prevention of dental caries of claim 8, wherein the mammal to be treated is a dog or a cat.

0

# INTERNATIONAL SEARCH REPORT

ational Application No

US 00/23277

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K39/40 A61P31/04 A61K7/16 //C07K16/12,C07K16/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>SHARMA ARUN K ET AL: "Transgenic plants for the production of edible vaccines and antibodies for immunotherapy." CURRENT SCIENCE, vol. 77, no. 4, 25 August 1999 (1999-08-25), pages 524-529, XP001002438 Bangalore abstract page 524, right-hand column, paragraph 2 -page 525, left-hand column, paragraph 2 page 527, left-hand column, paragraph 3 -right-hand column, paragraph 1 page 528, left-hand column, paragraph 2 -right-hand column, paragraph 1</p> <p style="text-align: center;">-/--</p>	1-13,15

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*Z\* document member of the same patent family

Date of the actual completion of the international search

4 July 2001

Date of mailing of the international search report

17/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Bazzanini, R

## INTERNATIONAL SEARCH REPORT

 ational Application No  
 PCT/US 00/23277

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indicator, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 046 037 A (LEHNER THOMAS ET AL) 4 Apr 11 2000 (2000-04-04) column 1, line 13-17 column 4, line 59-63 column 5, line 22-24, 41-45 column 5, line 61 -column 6, line 11 column 6, line 63-67 column 19, line 55-62 column 20, line 5-31, 50-56 column 21, line 37-43 column 33, line 19-23, 31-34 examples 1-6 claims 1, 2, 20, 22 ---	1-13, 15
X	WO 00 11037 A (SHI WENYUAN ; HUME WYATT (US); UNIV CALIFORNIA (US)) 2 March 2000 (2000-03-02) page 1, line 16-21 page 6, line 1-16 page 9, line 10-12 page 14, line 18-21 page 15, line 5-9 page 16, line 29 -page 17, line 2 page 17, line 19-21 page 18, line 26 -page 19, line 4 claims 1-3 ---	1-3, 6-9, 12
X	DATABASE WPI Section Ch, Week 199033 Derwent Publications Ltd., London, GB; Class B04, AN 1990-252063 XP002168341 & JP 02 177899 A (NAGASE SANGYO KK), 10 July 1990 (1990-07-10) abstract ---	1, 2, 6-8, 12
X	US 5 352 446 A (LEHNER THOMAS) 4 October 1994 (1994-10-04) cited in the application ---	1, 2, 6, 7
A	column 2, line 16-62 column 3, line 46-57 example 2 claims 1-3 ---	17
X	DATABASE WPI Section Ch, Week 199340 Derwent Publications Ltd., London, GB; Class B04, AN 1993-316577 XP002168342 & JP 05 227916 A (KANEBO LTD), 7 September 1993 (1993-09-07) abstract ---	1, 7

-/-

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/23277

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 2 143 829 A (KITASATO INST) 20 February 1985 (1985-02-20) page 2, line 40-57, 108-124 page 3, line 84 -page 4, line 20 examples 5-8 page 6, line 22-75 claims 1,8-12 ---	1,7
X	EP 0 140 498 A (LION CORP) 8 May 1985 (1985-05-08) page 3, line 8-28 page 6, line 17-19 page 9, paragraph 3 examples 2-18 claims 1-4, 13-15 ---	1,7
X	DATABASE WPI Section Ch, Week 199423 Derwent Publications Ltd., London, GB; Class B04, AN 1994-186363 XP002168343 & JP 06 122633 A (LION CORP), 6 May 1994 (1994-05-06) abstract ---	1,7
X	EP 0 334 467 A (GEN CORP KK ;KANEBO LTD (JP)) 27 September 1989 (1989-09-27) page 1, line 4-6 page 7, line 1-5, 12, 13 claims 4-7 -----	7

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/23277

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6046037	A	04-04-2000	AU 722668 B	10-08-2000
			AU 4608896 A	24-07-1996
			CA 2208783 A	11-07-1996
			CN 1183802 A	03-06-1998
			EP 0807173 A	19-11-1997
			JP 11504901 T	11-05-1999
			WO 9621012 A	11-07-1996
WO 0011037	A	02-03-2000	AU 5576399 A	14-03-2000
			EP 1105425 A	13-06-2001
			US 6231857 B	15-05-2001
JP 2177899	A	10-07-1990	NONE	
US 5352446	A	04-10-1994	NONE	
JP 5227916	A	07-09-1993	NONE	
GB 2143829	A	20-02-1985	JP 1916220 C	23-03-1995
			JP 4063864 B	13-10-1992
			JP 60028937 A	14-02-1985
			AU 3088984 A	31-01-1985
			DE 3427477 A	05-06-1985
			KR 8904123 B	21-10-1989
			US 5240704 A	31-08-1993
EP 0140498	A	08-05-1985	JP 1730543 C	29-01-1993
			JP 4021649 B	13-04-1992
			JP 60038329 A	27-02-1985
			AT 43496 T	15-06-1989
			DE 3478395 D	06-07-1989
			US 4693888 A	15-09-1987
JP 6122633	A	06-05-1994	NONE	
EP 0334467	A	27-09-1989	JP 1190635 A	31-07-1989
			JP 2641228 B	13-08-1997
			CA 1325192 A	14-12-1993
			CN 1036036 A, B	04-10-1989
			DE 68921908 D	04-05-1995
			DE 68921908 T	27-07-1995
			KR 9410861 B	18-11-1994
			US 5439680 A	08-08-1995
			US 5281524 A	25-01-1994